louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06624319: Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
Official title: Comparing the Analgesic Effect of Two Different Doses of Dexmedetomidine Added to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Lower Abdominal Cancer Surgeries; A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Post Operative Pain
Keywords: Tap block
Dexmedetomidine
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-10-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients will receive pre-emptive ultrasound-guided tap block with two different doses of dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.
Primary purpose: TREATMENT

Brief summary: The aim of this study to determine the optimal dose of dexmedetomidine as an adjuvant to bupivacaine in U.S guided TAP block for preemptive analgesia In patients undergoing lower abdominal cancer surgeries.

Detailed description: The transversus abdominis plane (TAP) involves innervations of the anterolateral abdominal wall derived from T6-L1. The block can be given either by anatomical landmark technique or by using an ultrasound probe. The local anesthetic is deposited in a plane between internal oblique and transversus abdominis muscle. It provides adequate postoperative analgesia following various abdominal surgeries.Dexmedetomidine is an alpha-2 agonist that has been approved as a venous sedative and an adjuvant for pain relief .In previous studies, the addition of dexmedetomidine to bupivacaine in the TAP block has prolonged the effect of this block . So far, the optimal dose of dexmedetomidine for the TAP block has not been determined.

Eligibility criteria: Inclusion Criteria:

* age from 18 to 65 years old
* lower abdominal cancer surgery

Exclusion Criteria:

* patient refusal
* the local anesthetic allergy
* coagulopathy
* local infection at the procedure site
* psychic patients
* patient on chronic opioid use

Primary outcomes:
measure: Total morphine consumption during the first 24 hours postoperatively
timeFrame: First 24 hours postoperative
Secondary outcomes:
measure: Severity of pain using Visual analogue scale
timeFrame: First 24 hours postoperative
measure: Patient level of sedation using four point modified ramsy scale
timeFrame: First 24 hours postoperative
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: South egypt cancer institute,Assiut University
Study officials:
affiliation: Assiut University
name: Kerolos S Tawfeek
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04635319: Prevalence of Facial Asymmetry Among Orthodontic Patients
Official title: Prevalence of Facial Asymmetry Among PreOrthodontic Adult Patients: A Crosssectional Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Facial Asymmetry
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Only patient's age between 18-40 years old of both sexes who asked for orthodontic treatment will be included in this study.

Brief summary: To estimate the prevalence of facial asymmetry

Detailed description: The objectives of the present study are:

* To estimate the prevalence of facial asymmetry among Egyptian population, according to type, sex, and age.
* To provide an insight into the key aspects to be taken into consideration while accomplishing an accurate diagnosis and formulation of rational integrated orthodontic-surgical treatment plan that considers correction of all aspects of the asymmetry.

Eligibility criteria: Inclusion Criteria:

* between 18-40 years old of both sexes who asked for orthodontic treatment

Exclusion Criteria:

* • No previous orthodontic treatment.

  * photographs of poor quality.
  * Any hereditary diseases or syndromes such as Down's syndrome or cleidocranial dysostosis.
  * Any disease of the jaw that might have affected the normal growth of permanent dentition.

Primary outcomes:
measure: Type of facial asymmetry
timeFrame: Just before the orthodontic treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dentistry Cairo university
Study officials:
References:
Clinical trial NCT01247519: The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department
Official title: The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: General Medical Disease
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2010-11-24
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The investigators will perform and evaluate a post-hospitalization telecare system for compensating the discontinuity from the hospitalist care system.

Detailed description: At present, Taiwan's population has become an aging society since recent decade. Those older than 65 years had achieved 10.4% in 2008. Meanwhile, the proportion of hosts with underlying comorbid illness or immunocomprised status is increasing worldwide. In the trend of aging population, telehealth care will be important to extend the care system in post-hospitalization home care. In the past, thelehealth care has shown a good executive performance in the patients with congestive heart failure and post-operation follow-up. However, in dealing the patients with acute illness needing hospitalization, the telehealth system has not implemented yet. In regard to National health insurance (NHI) of Taiwan, hospitalization costs a lot in overall budget. Reduction of re-hospitalization in those with/without co-morbidity is a important issue for Taiwan NHI. Therefore, we plan to conduct the telehealth care system in post-hospitalization course in those admitted from emergency department. We observe the re-hospitalization rate and analyze the risk factors. In addition, we hypothesize the telehealth care will decrease the rate of re-hospitalization.

Eligibility criteria: Inclusion Criteria:

* Older than 18 years
* Discharged alive from our hospitalist-care ward to home care
* Match diagnosis of general medicine

Exclusion Criteria:

* Younger than 18 years
* Discharged to care facility other than home
* Died in hospital
* Communication deficits
* No telephone at home
* Patient or family refused

Primary outcomes:
measure: readmission
timeFrame: within 30 days after discharge
Secondary outcomes:
measure: vist of emergency department
timeFrame: within 30 days after discharge
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Chin-Chung Shu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02837419: Cost-effectiveness of Extracorporeal Life Support Treatment
Official title: A Multicenter Prospective Observational Cohort Study Determining the Cost-effectiveness of Extracorporal Life Support (ECLS) Treatment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critically Ill
Keywords: extracorporeal life support
health related quality of life
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
First posted: 2016-07-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Critically ill patients on the ICU treated with extracorporeal life support

Brief summary: This study evaluates patients on ECLS treatment as considered appropriate with mortality and health related Quality of life and costs.

Detailed description: A direct comparison between usual care and ECLS treatment is difficult. Alternatively we compare predicted mortality for every patient based on validated scoring systems at the initiation of ECLS treatment with the actual outcome, so every patient is his own control.

Primary outcome is HRQoL assessed with the EQ-5D questionnaire at 1 year. Healthcare costs and costs from a societal perspective are prospectively measured.

Eligibility criteria: Inclusion Criteria:

* Admitted to intensive care
* Treated with extracorporeal life support

Exclusion Criteria:

* none

Primary outcomes:
measure: health related quality of life
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen
Study officials:
affiliation: department of critical care, UMCG
name: walter m van den Bergh, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oude Lansink-Hartgring A, Dos Reis Miranda D, Donker DW, Maas JJ, Delnoij T, Kuijpers M, van den Brule J, Scholten E, Endeman H, Vlaar APJ, van den Bergh WM; Dutch ECLS study group. Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands. BMC Health Serv Res. 2018 Mar 9;18(1):172. doi: 10.1186/s12913-018-2964-6.
Clinical trial NCT01676519: Impact of Critical Limb Ischemia on Long Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Limb Ischemia
Lead sponsor: Ospedale San Donato
Sponsor class: OTHER
First posted: 2012-08-31
Enrollment: 764
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: consecutive diabetic patients undergoing percutaneous coronary intervention

Brief summary: Prospective cohort study of consecutive diabetic patients undergoing percutaneous coronary intervention (PCI) in whom development of critical limb ischemia was prospectively assessed by a dedicated diabetic foot clinic. Cardiac mortality at 4-year follow-up was the primary endpoint of the study.


Eligibility criteria: Inclusion Criteria:

* diabetes mellitus
* need for coronary revascularization
* age \> 18 years

Exclusion Criteria:

* clinical contraindications to prolonged double antiplatelet therapy
* life expectancy \< 1 year
* lack of consent

Primary outcomes:
measure: cardiac mortality rate
timeFrame: 4-year follow-up
Secondary outcomes:
measure: major adverse cardiac event rate
timeFrame: 4-year follow-up
Other outcomes:
Locations:
city: Arezzo
country: Italy
facility: Cardiovascular Department, Ospedale S.Donato
state: AR
Study officials:
References:
citation: Liistro F, Angioli P, Grotti S, Brandini R, Porto I, Ricci L, Tacconi D, Ducci K, Falsini G, Bellandi G, Bolognese L. Impact of critical limb ischemia on long-term cardiac mortality in diabetic patients undergoing percutaneous coronary revascularization. Diabetes Care. 2013 Jun;36(6):1495-500. doi: 10.2337/dc12-1603. Epub 2013 Jan 22.
Clinical trial NCT00906919: The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes
Official title: The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Keywords: self-efficacy
health behavior
patient education
health education
Lead sponsor: University of Victoria
Sponsor class: OTHER
Collaborators: name: Vancouver Foundation
First posted: 2009-05-21
Enrollment: 321
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this randomized controlled trial is to determine if greater effectiveness can be achieved by the addition of lay-led self-management patient education to regular professionally-led diabetes patient education in comparison to regular professionally-led diabetes patient education only.

Detailed description: In the current health care environment, it is unacceptable for patient education programs to merely provide information. Rather, educational programs must concentrate on behavior change and on supporting patients to become more confident and motivated in participating in managing their health. Persons with type 2 diabetes attending a Diabetes Education Centre will be assigned to either a group that receives regular professionally-led diabetes patient education (control group) or to to a group that receives regular professionally-led diabetes patient education augmented by lay-led self-management education i.e., the Stanford six-session Chronic Disease Self-Management Program (experimental group). Data will be collected at two points in time (0 and 6 months). Outcome measures will show if participants who receive self-management training in addition to regular patient education are able to:manage their diabetes more effectively; engage in the specific behaviors that keep the condition from worsening; achieve more control over their condition; and use the health care system more effectively.

Eligibility criteria: Inclusion Criteria:

* adults with type 2 diabetes

Exclusion Criteria:

* cognitive impairment
* unable to speak English

Primary outcomes:
measure: A1C
timeFrame: 6 months
Secondary outcomes:
measure: Self-management behaviors
timeFrame: 6 months
measure: Self-efficacy levels
timeFrame: 6 months
measure: Health status
timeFrame: 6 months
measure: Cholesterol levels
timeFrame: 6 months
Other outcomes:
Locations:
city: Delta
country: Canada
facility: University of Victoria - Centre on Aging (Ladner Office), Suite 210, 4907 Chisholm Street
state: British Columbia
Study officials:
affiliation: University of Victoria
name: Patrick T McGowan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02195219: Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Dislocations
Official title: Clinical Trial to Compare the Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Grade III Dislocations
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acromioclavicular Joint Dislocation
Keywords: conservative
treatment
surgical
Acromioclavicular
Joint
dislocation
Lead sponsor: Hospital General Universitario Gregorio Marañon
Sponsor class: OTHER
First posted: 2014-07-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare two therapeutical procedures for the grade III acromioclavicular dislocations, either open reduction and internal fixation with a coracoclavicular device (MINAR-STORZ ) or non operative treatment.

For these purpose we have designed an interventional, prospective, parallel assignment, opened and randomized study.

Detailed description: Acromioclavicular dislocations are one of the most frequent traumatic lesions of the scapular girdle. They represent the 40-50% of the sport related shoulder injuries.

There are different grades of dislocations being classified by Altman- Rockwood in 6 types. There is consensus for non operative treatment in types 1 and 2 and for surgical treatment in types 4, 5 and 6.

For type 3 both therapeutic techniques are accepted with no high scientific evidence studies supporting either of them.

During de 70's, surgical treatment was recommended for all these lesions but in the early 90´s surgeons´s preferences changed into the non-operative treatment. Now a day, treatment is decided according to the surgeon experience and the functional demands of the patient.

The aim of this study is to compare the results of non-operative treatment and open reduction and internal fixation with a coracoclavicular reconstruction device (MINAR-STORZ) in grade III acromioclavicular dislocations.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 50 years.
* Grade III acromioclavicular dislocation.
* Signed informed consent.

Exclusion Criteria:

* Any condition that may impair the functional recovery or the patient collaboration with the rehabilitation program (cognitive disability, neurological pathology, tumoral disease...).
* Previous acromioclavicular osteoarthritis.
* Previous acromioclavicular lesions.
* Concomitant lesions in the ipsilateral limb or in the contralateral shoulder.
* Polytraumatized patients.
* Any disease or condition the investigator finds decisive for exclusion.

Primary outcomes:
measure: Efficacy
timeFrame: 12 months
Secondary outcomes:
measure: X-ray evaluation
timeFrame: 12 months
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Servicio de Cirugía Ortopédica y Traumatología, HGU Gregorio Maranon
Study officials:
affiliation: Hospital Heneral Universitario Gregorio Maranon
name: Mikel Aburto, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00285519: Japan Morning Surge-1 Study
Official title: The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Morning hypertension
Lead sponsor: Japan Heart Foundation
Sponsor class: OTHER
First posted: 2006-02-02
Enrollment: 600
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine whether strict blood pressure (BP) control by doxazosin using home BP monitoring, especially targeting the morning BP level, can reduce hypertensive target organ damage.

Detailed description: Morning blood pressure may play an important role in the pathogenesis of hypertensive target organ damage. Increased sympathetic nerve activity is reported to be one of the mechanisms of morning hypertension; however, there are no available data that show whether strict home blood pressure control, especially in the morning period, can reduce target organ damage.We will evaluate whether strict morning blood pressure control by sympathetic nervous system blockade using an alfa-blocker, doxazosin, and with the addition of a beta-blocker if needed, can reduce hypertensive target organ damage.

Eligibility criteria: Inclusion Criteria:

* Morning systolic blood pressure \>135 mmHg in a sitting position at home while on stable antihypertensive medication for at least 3 months

Exclusion Criteria:

* History of heart failure
* Presence of orthostatic hypotension, dementia, malignancy and chronic inflammatory disease
* Taking an alfa-blocker or beta-blocker
* Atrial fibrillation or atrial flutter

Primary outcomes:
measure: brain natriuretic peptide and the urinary albumin excretion/creatinine ratio at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shimotsuke
country: Japan
facility: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine
state: Tochigi
Study officials:
affiliation: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine
name: Kazuomi Kario, MD, PhD
role: STUDY_CHAIR
References:
citation: Hoshide S, Parati G, Matsui Y, Shibazaki S, Eguchi K, Kario K. Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin. Hypertens Res. 2012 Jan;35(1):100-6. doi: 10.1038/hr.2011.156. Epub 2011 Sep 15.
Clinical trial NCT07015918: A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men
Official title: A PHASE 1, OPEN-LABEL, 2-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF [14C]PF-07976016 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07976016 IN HEALTHY MALE PARTICIPANTS USING A [14C]-MICROTRACER APPROACH
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy Male Volunteers
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2025-06-11
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to learn about how much the study medicine PF-07976016 will be taken up and processed by healthy male participants. The total number of weeks of the study is up to approximately 12 weeks.


Eligibility criteria: Inclusion Criteria:

* Males, 18 to 65 years of age
* BMI 17.5 to 32 kg/m2 and a total body weight \>50 kg (110 lb)
* Willing and able to comply with all study procedures

Exclusion Criteria:

* History of irregular bowel movements or lactose intolerance
* Any medical or psychiatric condition or laboratory abnormality or other condition that may increase the risk of study participation
* Use of any prohibited or concomitant medication(s)
* Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
* Positive urine drug test
* History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
* Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day
* Previous administration of an investigational product within 30 days preceding the first dose of study medicine in this study.

Primary outcomes:
measure: Total recovery of radioactivity expressed as a percent of total oral radioactive dose administered.
timeFrame: From dose (Day 1) and for up to 21 days thereafter
Secondary outcomes:
measure: Number of participants with treatment emergent adverse events
timeFrame: First dose (Day 1) through 28 to 35 days after final dose (approximately 12 weeks)
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: ICON
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: